Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican-3-derived peptide

Identification of an H2-Kb or H2-Db restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide

(2013) TATSUAKI IWAMA et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccination

(2013) Yu Sawada et al.   Human Vaccines & Immunotherapeutics

Peptide vaccines for hepatocellular carcinoma

(2013) Daisuke Nobuoka et al.   Human Vaccines & Immunotherapeutics

Phase I Trial of a Glypican-3-Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival

(2012) Y. Sawada et al.   CLINICAL CANCER RESEARCH

Analysis of Genetic Damage and Gene Polymorphism in Hepatocellular Carcinoma (HCC) Patients in a South Indian Population

(2012) Subramaniam Mohana Devi et al.   DIGESTIVE DISEASES AND SCIENCES

Conditional ligands for Asian HLA variants facilitate the definition of CD8+T-cell responses in acute and chronic viral diseases

(2012) Cynthia X. L. Chang et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Structural and functional distinctiveness of HLA-A2 allelic variants

(2012) Kenneth Yuanxiang Chen et al.   IMMUNOLOGIC RESEARCH

A glypican-3-derived peptide vaccine against hepatocellular carcinoma

(2012) Yu Sawada et al.   OncoImmunology

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells

(2011) Toshiaki Yoshikawa et al.   CANCER SCIENCE

Biased usage of T cell receptor β-chain variable region genes of Wilms’ tumor gene (WT1)-specific CD8+ T cells in patients with solid tumors and healthy donors

(2011) Soyoko Morimoto et al.   CANCER SCIENCE

Molecularly Targeted Therapies for Hepatocellular Carcinoma: Sorafenib as a Stepping Stone

(2011) Hwi Young Kim et al.   DIGESTIVE DISEASES

Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma

(2011) Eishiro Mizukoshi et al.   HEPATOLOGY

Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib

(2011) Manabu Morimoto et al.   HEPATOLOGY RESEARCH

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

(2010) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma

(2009) Hirofumi Shirakawa et al.   CANCER SCIENCE

Biased usage of BV gene families of T-cell receptors of WT1 (Wilms’ tumor gene)-specific CD8+T cells in patients with myeloid malignancies

(2009) Yukie Tanaka-Harada et al.   CANCER SCIENCE

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE